Analysts rate LAVA Therapeutics NV (LVTX:NSD) with a Strong Buy rating and a $15 target

SVB Leerink maintains the outperform rating with $28 LVTX stock price target.

Based on the LAVA Therapeutics Stock Forecast from 2 analysts, the average analyst LVTX stock price target is USD 15.50 over the next 12 months. LAVA Therapeutics NV’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of LVTX stock forecast is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, LAVA Therapeutics stock price was USD 4.74LAVA Therapeutics stock price has changed by +2.34% over the past week, +2.23% over the past month and -22.23% over the last year.

 

About LAVA Therapeutics NV (LVTX:NSD):

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

 

Most Recent Analyst Ratings for LVTX’s Stock:

Maintains SVB Leerink Outperform USD 25 » USD 28 2022-09-27
Initiates Coverage On JMP Securities Market Outperform USD 6 2022-09-15
Target Up SVB Leerink Outperform USD 25 2022-05-18
Maintains SVB Leerink Outperform USD 24 » USD 20 2021-11-16
Maintains SVB Leerink Outperform USD 26 » USD 24 2021-08-17
Initiated by SVB Leerink Outperform USD 26 2021-04-19
Initiated by Jefferies Financial LLC Buy USD 23 2021-04-19
Initiated by JP Morgan & Company Overweight USD 22 2021-04-19

 

 

What we like:

Low volatility:

The annual returns for LVTX stock have been stable and consistent compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings:

LVTX stock price is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value:

LVTX stock price is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity:

LAVA Therapeutics stock management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets:

LAVA Therapeutics stock management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow:

LAVA Therapeutics stock had positive total free cash flow in the most recent four quarters.

 

What we don’t like:

Low market capitalization:

LVTX stock is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns:

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns, the returns are unpredictable. Proceed with caution.

Below median dividend returns:

The average income yield of LVTX stock over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow:

LAVA Therapeutics stock had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis:

LVTX stock price is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth:

LVTX stock has shown below median earnings growth in the previous 5 years compared to its sector.